Clinical Trial Update: A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating SAGE-718 in individuals with mild cognitive impairment or mild dementia due to Alzheimer's disease has completed, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment
• Dementia

Drugs mentioned

• SAGE-718

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Mild Cognitive Impairment, Mild Dementia | Phase 2 | Status: COMPLETED | Results posted: 2025-06-18